Anup Marda
Fortuna: 189 000 $ al 31/05/2026
Fortuna: 189 000 $ al 31/05/2026
Anup Marda is currently Chief Financial & Accounting Officer at Cabaletta Bio, Inc. since 2019.
Formerly, Mr. Marda was Executive Director at US Pharmaceuticals, Inc. from 2012 to 2014 and VP, Head-Global Financial Planning & Analysis at Bristol Myers Squibb Co. from 2018 to 2019.
Education includes an undergraduate degree from Indian Institute of Technology Bombay and an MBA from Krannert School of Management.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CABALETTA BIO, INC. 0,05 % | 02/03/2026 | 50.000 ( 0,05 % ) | 189 000 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CABALETTA BIO, INC. | Director Financiero/CFO | 01/01/2019 |
| Empresas | Cargo | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2019 |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Director/Miembro de la Junta | 01/01/2014 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Health Technology |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Krannert School of Management
Krannert School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which discovers and develops engineered cell therapies for B cell-mediated autoimmune diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.